key: cord-0712507-loyfru3h
authors: Fiolet, Thibault; Kherabi, Yousra; MacDonald, Conor-James; Ghosn, Jade; Peiffer-Smadja, Nathan
title: Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review
date: 2021-10-27
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.10.005
sha: 4dfd0fe510d73f7830e7c6b2cc69cf3452b10764
doc_id: 712507
cord_uid: loyfru3h

BACKGROUND: Vaccines are critical cost-effective tools to control the COVID-19 pandemic. However, the emergence of SARS-CoV-2 variants may threaten the global impact of mass vaccination campaigns. OBJECTIVES: The objective of this study was to provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for nineteen COVID-19 vaccines. SOURCES: References for this review were identified through searches of PubMed, Google Scholar, BioRxiv, MedRxiv, regulatory drug agencies and pharmaceutical companies’ websites up to September 22nd, 2021. CONTENT: Overall, all COVID-19 vaccines had a high efficacy against the original strain and the variants of concern, and were well tolerated. BNT162b2, mRNA-1273 and Sputnik V had the highest efficacy (>90%) after two doses at preventing symptomatic cases in phase III trials. mRNA vaccines, AZD1222, CoronaVac were effective at preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta. Regarding observational real-life data, full immunization with mRNA vaccines and AZD1222 seems to effectively prevent SARS-CoV-2 infection against the original strain, Alpha and Beta but with reduced effectiveness against the Delta strain. A decline in infection protection was observed at 6 months for BNT162b2 and AZD1222. Serious adverse event rates were rare for mRNA vaccines (anaphylaxis: 2.5-4.7 cases per million doses), myocarditis (3.5 cases per million doses) and were similarly rare for all other vaccines. Prices for the different vaccines varied from $2.15 to $29.75 per dose. IMPLICATIONS: All vaccines appeared to be safe and effective tools to prevent severe COVID-19, hospitalization, and death against all variants of concern, but the quality of evidence greatly varied depending on the vaccines considered. There are remaining questions regarding booster dose and waning immunity, the duration of immunity and heterologous vaccination. COVID-19 vaccine benefits outweigh risks, despite rare serious adverse effect.

Pfizer/BioNte ch RNA-based 30 µg 5-7-dose vial 0.3mL per dose

Supplied as a frozen vial. The withdrawal of 6-7 doses from a single vial is dependent, in part, on the type of syringes and needles used to withdraw doses from the vials The vaccine must be diluted. Frozen vials prior to use can be stored before dilution: -80°C to -60°C up to the end of its expiry date or at -25°C to -15°C for up to two weeks Vials prior to dilution may be stored at +2°C to +8°C for up to 31 days or may be at room temperature up to +25°C for no more than 2 hours prior to use, or can be thawed in the refrigerator for 2-3 hours or at room temperature (up to +25°C) for 30 minutes.

After dilution: +2°C to +25°C Have to be used within 6 hours from the time of dilution A synthetic messenger ribonucleic acid (mRNA) encoding the Spike protein of SARS-CoV-2, lipids ((4hydroxybutyl)azanediyl)bis(hexa ne-6,1-diyl)bis ( 

Post-marketing surveillance studies results are summarized in Table 3 and detailed in Supplementary 163 Table 2 CoronaVac or BBIBP-COrV administration was associated with an effectiveness of 59% in China (57). 172 173

After full immunization (Figure 3) , mRNA vaccine or AZD1222 effectiveness against hospitalization 175 or death was over 87-94% (48,58) when the strain was not sequenced, 89-95% against Alpha 176 (36,38,39), 95% against Beta/Gamma (38), 96% against Alpha/Delta (39), 80-95% against Delta 177 (59,60). CoronaVac had a strong effectiveness against hospitalization (87.5%) and mortality (86.3%) 178 after full immunization(56). Ad26.COV1.S had an effectiveness of 60-85% against Delta (60,61). 179

Overall, mRNA-vaccine and CoronaVac effectiveness was reduced for Delta infection but they still 180 offered a high level of protection against severe COVID-19 and hospitalization for all variants after 181 full immunization (36,38,39,43,48,56,59,62,63). 182

After full immunization, effectiveness was 90-92% for AZD1222 or BNT162b2 against unspecified 184 strains (64,65) (Figure 4) led to an effectiveness of 78% against the original strain and 96% against Alpha, respectively. These 190 previous studies focused on 6 years people but a retrospective cohort of 12-15 years teenagers in 191

Israel also reported a high effectiveness of 91.5% against Delta infections (82). Waning immunity 213

Several studies suggested that the levels of antibodies after BNT162b2, mRNA-1273 and 214

Ad26.COV2.S vaccines could last for at least six months but decreased over time afterward (94-97). 215

For mRNA-1273, at 6 months, neutralizing activity was maintained against Alpha, Gamma, Delta, 216

Epsilon whereas neutralizing activity considerably decreased against Beta for half the participants 217

Observational studies stratified by time since vaccination identified a decreasing effectiveness at 4-6 219 months (42-57%) for mRNA vaccines and 47.3% for AZD1222 against Delta infection (54,68,69,81). 220

In the USA, effectiveness of mRNA vaccines against symptomatic infection reduced from 94.3% in 221

June to 65,5% in July 2021. The effectiveness against hospitalization remained high (>85%) for 222 mRNA-1273 (92%), BNT162b2 (77-93%) and AZD-1222 (70.3%) at 4-6 months after full vaccination 223 (54,69,81,98) and 68% at >28 days after full immunization for Ad26.COV2.S (98). It is difficult to 224 know if the reduction in effectiveness against Delta infection is due to waning immunity over time 225 or/and variants escaping immunity and/or increasing in collective immunity. 226 227 Neutralization assays with variants of concern and variants of interest 228 Mutations and variations occur in the SARS-CoV-2 virus due to evolution and adaptation processes 229 (99). Some SARS-CoV-2 variants of concern with mutations in the spike protein lead to an increased 230 transmissibility (100-105), which may be explained by an enhanced spike protein binding affinity for 231 the ACE2 receptor. For example, Alpha and Beta have been shown to have a 1.98-times and 4.62-232 times greater binding affinity than original strain (106). These variants may cause more severe disease 233

(4) and/or have a potential ability to escape the host or vaccine-inducted immune response (7,10). 234

Results from several seroneutralization assays assessing the neutralizing response of vaccine-induced 235 antibodies are described in Figure 5 and in Supplementary Table 3. In general, Alpha had a minimal 236 impact on neutralization activity of antibodies by post-vaccination sera ( Table 3) . Neutralization was 237 further reduced for variants with mutation E484K, and Gamma. Beta had the highest reduction in 238 neutralizing titers. Data were lacking for C.1.2 identified in South Africa in May, 2021 but C.1.2 had a 239 1.7-fold higher substation rate than the current global substitution rate (107) . 

More generally, evidence on the extension of the interval between doses is scarce. Trials for AZD1222 291

showed that a longer delay was better, but for mRNA and other vaccines, trials did not test different 292 dose gaps(163). A preprint reported that extending the interval to 6 weeks for BNT162b2 vaccine led 293 to higher titers in neutralizing antibodies and a sustained T cell response against the variants of 294 concerns (164). Another analyses found that a second dose at 12 weeks induced a stronger humoral 295 response than at a 3-week interval among older people(165). 296

Immunogenicity studies amongst transplant patients and patients with cancer showed a poor antibody 298 response after a single dose or two doses of Pfizer vaccine(166-168). Facing this issue, French, 299

German, British and the US health authorities have recommended a third dose for 300 immunocompromised people and transplant recipients. A randomized trial in transplant recipients 301 showed a third dose of mRNA-1273 was safe, and 26 out of 59 participants who had negative antibody 302 responses prior to the booster developed antibody responses after the third dose (169) . However, this 303 study did not look at cellular immune response. Another study found that an additional dose of 304 mRNA-1273 induced a serologic response among 50% of kidney transplant recipients not responding 305 after two doses (170). A case-control study in preprint found an effectiveness against SARS-CoV-2 306 infection 14-20 days after the third dose increased by 79% (vs 2 nd dose) (171). Another observational 307 study in Israel found a booster dose reduced the rate of confirmed infections and severe disease by a 308 factor of 11.3 and 19.5, respectively, among elderly participants (172). Two studies also showed 309

Moderna boosters (at least 6 months after the 2 nd dose) and Pfizer booster (8-11 months after the 2 nd 310 dose) induced a strong humoral response against Beta (173) and other variants of concern (174). The 311 expected local and systemic adverse events were mild and moderate and similar to those after the 2 nd 312 dose. 313

Several neutralization assays have suggested that a single dose of BNT16b or mRNA-1273 among 315 previously infected subjects could boost the cross-neutralization response against emerging variants 316 such as Alpha, Beta or Gamma (121,175) . These studies have demonstrated the potential benefits of 317 vaccinating both non-infected and previously infected people. Finally, several studies suggested that a 318 single dose of mRNA vaccine may be sufficient to boost the antibody response in previously infected 319 subjects and that the benefit of the second dose may be small (176-180) . 

We did not find any comparative studies addressing post-authorization safety QaeVac

We did not find any comparative studies addressing post-authorization safety COVIran Barkat We did not find any comparative studies addressing post-authorization safety Observational studies, unlike randomized studies, cannot guarantee comparability in the exposition of 361 different populations to SARS-CoV-2 and to the variants of concern. Indeed, real world studies 362 present large variations in time post-vaccination, exposition to SARS-CoV-2 strain, susceptibility to 363 infection (previously infected or not), study population (healthcare workers, older adults, 364 immunocompromised, chronical medical conditions, etc.). Moreover, due to a lack of randomization, 365 observational studies are subject to bias when assessing effectiveness, such as misclassification from 366 diagnostic errors, imbalances in socioeconomic status, exposure risk, health care seeking behaviours, 367 or immunity status between vaccinated and unvaccinated groups. Not all the observational studies 368 used adjustments to take into account confounding biases. For example, healthcare workers treating 369 COVID-19 patients may be more frequently exposed to SARS-CoV-2, leading to decreased estimates 370 of effectiveness. Various designs (cohort, case-control study, test-negative design (TND)) were used 371 in observational studies, each of them having limitations. Cohorts require large sample size for 372 uncommon outcomes (i.e. severe COVID-19) but vaccination status may be more difficult to 373 determine in retrospective cohorts. In case-control studies, vaccinated people may be more likely to 374

seek health care and SARS-CoV-2 testing, biasing toward a reduction in the estimation of Confidence intervals are delimited by the grey rectangular area. Blue, orange, red, pale blue, green refers to Alpha, Beta, Delta, Gamma and not sequenced strain, respectively. Tables   Table 1: Characteristics of COVID-19 vaccines   Table 2: Phase III Trials for COVID-19 vaccines   Table 3: COVID-19 vaccines and variants   Table 4 : Main severe adverse effect following COVID-19 vaccination in observational studies and pharmacovigilance systems

Draft landscape and tracker of COVID-19 candidate vaccines 415

Assessing transmissibility 418 of SARS-CoV-2 lineage B.1.1.7 in England

Model-420 based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant

Increased mortality in 423 community-tested cases of SARS-CoV-2 lineage B.1.1.7

Risk of 425 mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort 426 study

Genomics and 428 epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Sensitivity of 431 infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Neutralizing Antibodies Against SARS-CoV-434 2 Variants After Infection and Vaccination

Resistance of SARS-CoV

1.351 and B.1.1.7 to Antibody Neutralization

Escape of SARS-CoV-2 501Y.V2 438 from neutralization by convalescent plasma

V2 escapes neutralization by South African COVID-19 donor plasma

Direct gene transfer into 443 mouse muscle in vivo

History of vaccination

Safety and Efficacy of 446 the BNT162b2 mRNA Covid-19 Vaccine

Safety and Efficacy 448 of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Efficacy and Safety of the 454 mRNA-1273 SARS-CoV-2 Vaccine

Efficacy of 457 the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

Press release. CureVac Final Data from Phase 2b/3 Trial of First-Generation

Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

Efficacy of ChAdOx1 nCoV-465 19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an 466 exploratory analysis of a randomised controlled trial. The Lancet [Internet]. 30 mars 2021

Safety and efficacy 470 of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four 471 randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Efficacy of the ChAdOx1 474 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 476 at interim analysis

Effectiveness of 602 the Single-Dose Ad26.COV2.S COVID Vaccine

FDA-606 authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across 607 a multi-state health system

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19

MMWR 611 Morb Mortal Wkly Rep

Effect of Vaccination on 614 Transmission of SARS-CoV-2

An 616 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome

Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by 618

Clin Infect Dis

Impact of Delta 621 on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK 622

BNT162b2 625 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar 626

Comparison 629 of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant 630 prevalence

Interim Estimates of 637 Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-638

CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and 639

MMWR Morb Mortal 640 Wkly Rep

BNT162b2 643 mRNA Covid-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection: a preliminary 644 report

Effectiveness of BNT162b2 647 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers

Multicentre Prospective Cohort Study (the SIREN Study)

Social Science Research Network; 2021 févr

BNT162b2 Vaccine 652 Effectiveness in Preventing Asymptomatic Infection with SARS-CoV-2 Virus: A Nationwide 653

Historical Cohort Study

Social Science Research Network; 2021 mars 654

Vaccine 657 effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term 658 care facility residents and healthcare workers -a Danish cohort study

Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened 662 Workforce

Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural

Molecular Screening

SARS-CoV-2 Vaccine Effectiveness in a High-Risk 669 National Population in a Real-World Setting

Prevention of COVID-19 by 671 mRNA-based vaccines within the general population of California

REACT-1 round 13 final report: 674 exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with 675 Delta variant in England during

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among 678

Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight

Effectiveness of 682 mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the 683 USA: a retrospective cohort study. The Lancet

Early Release -Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-686

-687 Emerging Infectious Diseases journal -CDC

Prevention and 690 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Initial report of 693 decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by 696 Vaccination Status

Brown CM. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough 700 Infections

Virological and serological 704 kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort 705 study

Virological 708 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers 709

Effect of Vaccination on 712 Household Transmission of SARS-CoV-2 in England

Vaccination with 714 BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

High coverage COVID-19 mRNA vaccination 717 rapidly controls SARS-CoV-2 transmission in Long-Term Care Facilities

Transmission dynamics and 720 epidemiological characteristics of Delta variant infections in China

Risk factors and disease 724 profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study 725 app: a prospective, community-based, nested, case-control study

Antibody 733 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Dynamics of antibody 736 response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg 737 Health -Eur

Durability of mRNA-1273 740 vaccine-induced antibodies against SARS-CoV-2 variants

Comparative Effectiveness of Moderna

Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without 743 Immunocompromising Conditions -United States

No evidence for increased 747 transmissibility from recurrent mutations in SARS-CoV-2

CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. 751 medRxiv

Emergence 753 and rapid spread of a new severe acute respiratory syndrome

CoV-2) lineage with multiple spike mutations in South Africa

Estimated 757 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Public Health England. SARS-CoV-2 variants of concern and variants under investigation

Increased 763 transmissibility and global spread of SARS-CoV-2 variants of concern as at

Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) for 766 the Scientific Advisory Group for Emergencies (SAGE). SPI-M-O: Consensus statement on 767 COVID-19

SARS-CoV-2 B.1.1.7 and B.1.351 spike 771 variants bind human ACE2 with increased affinity

The continuous 775 evolution of SARS-CoV-2 in South Africa: a new lineage with rapid accumulation of mutations 776 of concern and global detection

Hospital 784 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared 785 with alpha (B.1.1.7) variants of concern: a cohort study

Neutralizing Activity of 789 BNT162b2-Elicited Serum

Neutralization of SARS-CoV-2 spike 791 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

.351 and P.1 escape from neutralizing antibodies

CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Two doses of 800 SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 801 variants of concern than does natural infection

CoV-2 variants escape neutralization by vaccine-induced humoral immunity

CoV-2 variants by convalescent and vaccinated serum. medRxiv. 9 avr 809 2021

Reduced neutralization of 811 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Qualitatively 814 distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants

mRNA vaccine-elicited 817 antibodies to SARS-CoV-2 and circulating variants

1 strain of SARS-CoV-2. Cell [Internet]. 30 mars 2021

Neutralizing Response 822 against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

Ineffective 825 neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera

mRNA-1273 vaccine 829 induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Susceptibility of Circulating 832 SARS-CoV-2 Variants to Neutralization

Neutralization of UK-834 variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv

Serum neutralising activity against SARS-CoV-2 837 variants elicited by CoronaVac

Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda

SARS-CoV-2 variant B.1.1.7 is 845 susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

Neutralization of SARS-CoV-2 VOC 501Y.V2 848 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD 849 ZF2001 vaccines

851 Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant 852 spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies

Infection-and 855 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

1.429 and B.1.351

Reduced neutralisation of 860 the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

Infectious Diseases (except HIV/AIDS); 2021 juin

S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of 865 concern

Temporal 867 Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape 868 after Sputnik V Vaccination

Infection and Vaccine-871 Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Comparison of 875 Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-876

CoV-2 Variants. bioRxiv. 19 juill 2021

Serum Neutralizing Activity of 878 mRNA-1273 against SARS-CoV-2 Variants

BNT162b2-elicited neutralization of 880 B.1.617 and other SARS-CoV-2 variants

Reduced 882 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Neutralising capacity 886 against Delta (B.1.617.2) and other variants of concern following Comirnaty

BioNTech/Pfizer) vaccination in health care workers

SARS-CoV-2 B.1.617.2 890 Delta variant replication and immune evasion

Reduced neutralization of SARS-CoV-2 B.1.617 893 variant by inactivated and RBD-subunit vaccine

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern 896 (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. 897 Vaccines

Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees. Clin Infect Dis

CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection 903 and vaccination. bioRxiv. 5 mai 2021

Vaccine 905 effectiveness against infection with the Delta (B.1.617.2) variant, Norway

Transmission, 908 infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California 909 carrying a L452R spike protein mutation

A Novel and 911 Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York

Reduced 914 neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1

B.1.1.7+E484K and a sub-variant of C.37 [Internet]. 2021 juill

SARS-CoV-2 immune evasion 919 by variant B.1.427/B.1.429

BNT162b2-Elicited Neutralization 921 against New SARS-CoV-2 Spike Variants

CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine

Disponible sur: 925

SARS-CoV-2 Lambda 927 Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies

Neutralizing antibody 931 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

BNT162b2 vaccine 934 induces neutralizing antibodies and poly-specific T cells in humans

Low dose mRNA-937 1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-938 existing crossreactive T cell memory

Evidence of SARS-Cov-2-942 specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine

COVID-19 vaccination: initial reactogenicity data. The Lancet

Un ensayo clínico evaluará una segunda dosis de la vacuna de 950

Pfizer en personas ya vacunadas con una dosis de AstraZeneca

Safety and 954 immunogenicity of heterologous versus homologous prime-boost schedules with an 955 adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, 956 non-inferiority trial. The Lancet

Induction of robust neutralizing antibodies 958 against the COVID-19 Delta variant with ChAdOx1 nCoV-19 or BNT162b2 as a booster 959 following a primary vaccination series with CoronaVac

Single-dose 963 administration and the influence of the timing of the booster dose on immunogenicity and 964 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. 965 The Lancet. 6 mars 2021

Strong humoral 967 immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 968 sixteen-week interval between doses

Extended interval 972 BNT162b2 vaccination enhances peak antibody generation in older people

Safety 976 and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients 977 with cancer: interim analysis of a prospective observational study

Immunogenicity of 981 a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. 982 JAMA

High seroconversion rate 984 but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients 985 treated with chemotherapy for solid cancers

Randomized Trial of a 989 Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Antibody 991 Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 992 Recipients With Minimal Serologic Response to 2 Doses

Short Term Reduction in 994 the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three 995 doses of the BNT162b2 Vaccine

Protection 999 of BNT162b2 Vaccine Booster against Covid-19 in Israel

SARS-CoV-2 1001 Neutralization with BNT162b2 Vaccine Dose 3

Safety and immunogenicity of SARS-CoV-2 1003 variant mRNA vaccine boosters in healthy adults: an interim analysis

mRNA vaccination 1006 boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Antibody 1010 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Antibody Response in Persons with Past Natural Infection

Distinct 1015 antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals 1016 following mRNA vaccination

Poor 1019 antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-1020 experienced individuals

Single Dose 1022 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. medRxiv

COVID-19 vaccine safety update

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine 1029 Recipients: Update from the Advisory Committee on Immunization Practices -United States

MMWR Morb Mortal Wkly Rep

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Receipt of mRNA Covid-1036 19 Vaccines and Risk of Spontaneous Abortion

Clinical manifestations, risk 1038 factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living 1039 systematic review and meta-analysis

Surveillance for Adverse 1041

Events After COVID-19 mRNA Vaccination

1042 Disponible sur

Coronavirus vaccine -weekly summary 1044 of Yellow Card reporting

Safety of the BNT162b2 1048 mRNA Covid-19 Vaccine in a Nationwide Setting

Safety Monitoring of COVID-19 Vaccines in Hong Kong

Moderna COVID-19 Vaccine -United States

A Retrospective observational survey of 1058 adverse events following immunization comparing tolerability of covishield and covaxin 1059 vaccines in the real world

ROCCA observational 1063 study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San 1064 Marino using active surveillance

Active monitoring of early safety of Sputnik V vaccine in

Quinto Informe Estadistico: 1069 ESAVI asociados a la administracion de las vacunas SARS-CoV-2 en Chile

Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines

Potential adverse effects of COVID19 1076 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a 1077 retrospective cross-sectional study

Effectiveness of BNT162b2 and 1079 ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 1080 80 years: a test-negative, case-control study

Interim findings from first-1083 dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a 1084 national prospective cohort study

Early rate reductions of SARS-CoV-2 1086 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet. 6 mars

Experience of 1089 COVID-19 Vaccination of Healthcare Workers in a Hospital Setting

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two 1093 Skilled Nursing Facilities Experiencing COVID-19 Outbreaks -Connecticut

Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for 1098 COVID-19. medRxiv

Association 1100 Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women

Effectiveness 1103 of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant 1104 transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg Health -Am 1105